Biomea Fusion Q2 net loss narrows to $8.33 million; R&D expenses fall 44.68% to $9.14 million - BMEA News | RalliesBiomea Fusion Q2 net loss narrows to $8.33 million; R&D expenses fall 44.68% to $9.14 million
B
BMEA• Cash position and runway
- Cash, cash equivalents and restricted cash totaled USD 35.2 million at June 30, 2026; cash runway projected into the second quarter of 2027.
Program updates and expected data readouts
- COVALENT-211 Phase II data expected in Q1 2027.
- COVALENT-212 data expected in Q2 2027.
- Initial 28-day BMF-650 weight-loss data due Q3 2026.
Quarterly loss narrows as R&D and G&A expenses decline
- Biomea Fusion posted a net loss attributable to common stockholders of USD 8.3 million, narrowing from USD 20.7 million a year earlier.
- R&D expense fell to USD 9.1 million from USD 16.6 million, on lower external, personnel, manufacturing, and facilities-related costs.
- G&A expense declined to USD 3.6 million from USD 4.7 million, driven mainly by lower personnel-related costs on reduced headcount.
EQX
•
